DDInter1607 DDInter1544
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Ritonavir {u} (Compound) resembles {v} (Compound) Lopinavir
Ritonavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Ritonavir {u} (Compound) binds {v} (Gene) SLCO1A2
Ritonavir {u} (Compound) upregulates {v} (Gene) AGR2
Ritonavir {u} (Compound) is included by {v} (Pharmacologic Class) Breast Cancer Resistance Protein Inhibitors
Ritonavir {u} (Compound) downregulates {v} (Gene) NT5DC2
Ritonavir {u} (Compound) causes {v} (Side Effect) Blood triglycerides increased
Ritonavir (Compound) resembles Atazanavir (Compound)
Ritonavir (Compound) resembles Lopinavir (Compound)
Ritonavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Ritonavir (Compound) binds SLCO1A2 (Gene)
Ritonavir (Compound) upregulates AGR2 (Gene)
Ritonavir (Compound) is included by Breast Cancer Resistance Protein Inhibitors (Pharmacologic Class)
Ritonavir (Compound) downregulates NT5DC2 (Gene)
Ritonavir (Compound) causes Blood triglycerides increased (Side Effect)